🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

299 results for “AVI” Clear

  1. Vyvgart 1 000 mg solution for injection

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    Argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  4. Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Zilbrysq 32.4 mg solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  6. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  7. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  8. Zilucoplan sodium

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. bamlanivimab 7000mg

    SAB Biotherapeutics

    Coronavirus

    phase 3 mab completed

    1 trial

  10. behavior intervention and male circumcision

    China SXT Pharmaceuticals

    HIV

    phase 3 other active

    1 trial

  11. cisplatin

    China SXT Pharmaceuticals

    Oral Cavity

    phase 3 small molecule completed

    1 trial

  12. cognitive-behavioral withdrawal regulation strategies

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Dependence

    phase 3 other active

    1 trial

  13. maribavir

    Takeda Pharmaceuticals International AG

    Cytomegalovirus Infections

    phase 3 small molecule completed

    2 trials

  14. maribavir, Maribavir, LIVTENCITY 200 mg film-coated tablets., Maribavir

    Takeda Pharmaceuticals International AG

    Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)

    phase 3 small molecule active

    1 trial

  15. sapropterin

    BioMarin International Limited

    Behavioral Manifestations of Lesch-Nyhan Disease

    phase 3 small molecule terminated

    1 trial

  16. 851B

    Takeda Pharmaceuticals International AG

    Papillomavirus Infections

    phase 2 small molecule terminated

    2 trials

  17. ARGX-117, ARGX-113

    Argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  18. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  19. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  20. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  21. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule completed

    1 trial

  22. AVI-4658 (PMO)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  23. AVI-4658 for Injection

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  24. AVI-5126

    Sarepta Therapeutics

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources